BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma.

@article{Ribas2011BRIM2AO,
  title={BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma.},
  author={Antoni Ribas and Kevin B Kim and Lynn Mara Schuchter and Ricardo Gonz{\'a}lez and Anna C Pavlick and J S Weber and Grant Mcarthur and Thomas E. Hutson and Keith T Flaherty and Stergios J. Moschos and Donald P. Lawrence and Peter Hersey and Richard F Kefford and Bartosz Chmielowski and Igor Puzanov and Jinhui Li and Keith B Nolop and Rumi Lee and Andrew K. Joe and Jeffrey A. Sosman},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2011},
  volume={29 15_suppl},
  pages={8509}
}
8509 Background: Most agents tested in large phase II trials in patients (pts) with metastatic melanoma have response rates of 10-20%. Approximately 50% of melanomas harbor a V600E activating mutation in the BRAF gene, which can now be targeted with specific inhibitors. In a Phase I study, treatment with vemurafenib (V), an orally available inhibitor of mutant BRAF, led to a high incidence of tumor regressions in BRAF-mutant melanoma (Flaherty et al. NEJM 2010). Here we report the results of… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 75 CITATIONS, ESTIMATED 43% COVERAGE

Cardiac Toxicity of Targeted Therapies Used in the Treatment for Solid Tumours: A Review

  • Cardiovascular Toxicology
  • 2012
VIEW 5 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Activity of Imatinib Mesylate in Metastatic Anorectal Melanoma: A Case Report

  • Journal of Gastrointestinal Cancer
  • 2011
VIEW 3 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Practical Guide to Dermatology: The Henry Ford Manual

Henry W. Lim, Laurie Linden Kohen, Samantha L. Schneider, Danielle Yeager
  • 2020
VIEW 1 EXCERPT
CITES BACKGROUND

Targeting the ERK Signaling Pathway in Melanoma

  • International journal of molecular sciences
  • 2019
VIEW 2 EXCERPTS
CITES BACKGROUND

Therapeutic resistance and susceptibility is shaped by cooperative multi-compartment tumor adaptation

Jason E. Long, Matthew Wongchenko, +13 authors Melissa R Junttila
  • Cell Death & Differentiation
  • 2019
VIEW 1 EXCERPT
CITES METHODS

FILTER CITATIONS BY YEAR

2011
2020

CITATION STATISTICS

  • 5 Highly Influenced Citations